William Blair Issues Positive Outlook for NMRA Earnings

Neumora Therapeutics, Inc. (NASDAQ:NMRA) – Equities researchers at William Blair boosted their Q3 2025 EPS estimates for shares of Neumora Therapeutics in a research note issued to investors on Wednesday, August 6th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($0.28) per share for the quarter, up from their prior forecast of ($0.30). The consensus estimate for Neumora Therapeutics’ current full-year earnings is ($1.61) per share. William Blair also issued estimates for Neumora Therapeutics’ Q4 2025 earnings at ($0.29) EPS, FY2025 earnings at ($1.32) EPS, Q1 2026 earnings at ($0.27) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.22) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.91) EPS and FY2028 earnings at ($0.47) EPS.

Neumora Therapeutics (NASDAQ:NMRA) last released its earnings results on Wednesday, August 6th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.38) by $0.05.

NMRA has been the topic of several other research reports. Mizuho upped their price objective on shares of Neumora Therapeutics from $4.00 to $5.00 and gave the stock an “outperform” rating in a report on Wednesday, July 16th. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, May 13th. One research analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. According to MarketBeat, Neumora Therapeutics has a consensus rating of “Hold” and a consensus target price of $7.14.

Neumora Therapeutics Stock Performance

NMRA opened at $1.44 on Monday. The company has a current ratio of 10.54, a quick ratio of 10.54 and a debt-to-equity ratio of 0.11. The company’s fifty day moving average price is $1.25 and its two-hundred day moving average price is $1.17. Neumora Therapeutics has a 1-year low of $0.61 and a 1-year high of $17.19. The company has a market cap of $233.21 million, a price-to-earnings ratio of -0.92 and a beta of 2.91.

Institutional Trading of Neumora Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in NMRA. Capital International Investors raised its holdings in shares of Neumora Therapeutics by 692.1% in the fourth quarter. Capital International Investors now owns 3,700,359 shares of the company’s stock valued at $39,224,000 after purchasing an additional 3,233,179 shares during the last quarter. Lunate Capital Ltd purchased a new stake in shares of Neumora Therapeutics in the first quarter valued at about $2,124,000. Graham Capital Management L.P. raised its holdings in shares of Neumora Therapeutics by 1,643.7% in the first quarter. Graham Capital Management L.P. now owns 1,162,499 shares of the company’s stock valued at $1,162,000 after purchasing an additional 1,095,830 shares during the last quarter. AQR Capital Management LLC purchased a new stake in shares of Neumora Therapeutics in the first quarter valued at about $463,000. Finally, Stempoint Capital LP purchased a new stake in shares of Neumora Therapeutics in the fourth quarter valued at about $4,538,000. Hedge funds and other institutional investors own 47.65% of the company’s stock.

Neumora Therapeutics Company Profile

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.